Our annual Fierce 15 report on a top class of up-and-coming private biotechs came out today and I wanted to highlight the responses from many of the companies which are on the list. Read more | Check out this year's report
Last year when Ryan McBride and I were sorting through our short list of candidates, we both felt that Seaside Therapeutics deserved a spot on the list. The small company had raised a considerable...
Celgene's $13 million investment in Presage Biosciences' cancer drug delivery platform is a major bet on something groundbreaking. The technology is the first of its kind, with the ability to compare treatments across separate sections of a tumor.
Fast-moving Celgene has turned to Presage Biosciences to begin testing the potential of cancer drug combinations in animals, paying $5 million upfront to support the research and taking an $8 million equity stake in the up-and-coming biotech.
Presage Biosciences in Seattle reports that it is gaining some significant traction for its new approach to testing cancer drugs in mice. The Seattle-based biotech tells Xconomy that it has boosted